ERCC1 and non-small cell lung carcinoma: Here, we investigated the predictive role of two classical and readily assayable biomarkers, ERCC1 and p53, which are involved in the underlying mechanisms of NSCLC cell treatment with a combination of HDACis and cisplatin.